2025
Voxel-Wise Map of Intracerebral Hemorrhage Locations Associated With Worse Outcomes
Karam G, Chen M, Zeevi D, Harms B, Berson E, Torres-Lopez V, Rivier C, Malhotra A, Qureshi A, Falcone G, Sheth K, Payabvash S. Voxel-Wise Map of Intracerebral Hemorrhage Locations Associated With Worse Outcomes. Stroke 2025, 56: 868-877. PMID: 40052269, DOI: 10.1161/strokeaha.124.048453.Peer-Reviewed Original ResearchConceptsImpact of intracerebral hemorrhageAssociated with worse outcomesClinical risk factorsVoxel-wise mapsMapping of brain regionsBaseline hematomaVoxel-wise analysisHematoma volumeICH locationBrain regionsValidation cohortWorse outcomesPresence of intraventricular hemorrhageRisk factorsBaseline hematoma volumeModified Rankin Scale scorePoor scan qualityMulticenter clinical trialRankin Scale scoreDeep white matterLow-risk categoryComprehensive stroke centerIntraventricular hemorrhageConsecutive patientsPatient age
2024
Clinical outcomes of a twice-daily metronidazole dosing strategy for Bacteroides spp. bloodstream infections
Shah S, Adams K, Clarke L, Ludwig J, McManus D, Nguyen M, Topal J, Shields R. Clinical outcomes of a twice-daily metronidazole dosing strategy for Bacteroides spp. bloodstream infections. International Journal Of Antimicrobial Agents 2024, 65: 107403. PMID: 39667533, DOI: 10.1016/j.ijantimicag.2024.107403.Peer-Reviewed Original ResearchClinical failureDosing strategiesClinical outcomesIncreased risk of clinical failureRetrospective chart review of adult patientsChart review of adult patientsReview of adult patientsRate of clinical failureClinical outcomes of patientsRisk of clinical failureAssociated with worse outcomesOutcomes of patientsRetrospective chart reviewBloodstream infectionsMetronidazole doseAdult patientsWorse outcomesIncreased riskMetronidazolePatientsInclusion criteriaBacteroides sppBacteremiaDoseMortalityPractice Advisory on the Implementation of Preoperative Anemia Management: The Society of Cardiovascular Anesthesiologists and the Society for the Advancement of Patient Blood Management.
Klompas A, Hensley N, Burt J, Grant M, Guinn N, Patel P, Popescu W, Raphael J, Salenger R, Shore-Lesserson L, Warner M. Practice Advisory on the Implementation of Preoperative Anemia Management: The Society of Cardiovascular Anesthesiologists and the Society for the Advancement of Patient Blood Management. Anesthesia & Analgesia 2024 PMID: 39671507, DOI: 10.1213/ane.0000000000007321.Peer-Reviewed Original ResearchPatient blood managementAdvancement of Patient Blood ManagementBlood managementPreoperative anemiaCardiac surgeryAnemia managementRed blood cell transfusionAssociated with worse outcomesPreoperative anemia clinicPatient blood management programBlood cell transfusionAcute kidney injuryBlood management programPreoperative anemia managementImproving clinical outcomesSociety of Cardiovascular Anesthesiologists (SCASociety of Cardiovascular AnesthesiologistsAnemia programCell transfusionAnemia clinicEducation of patientsAllogeneic transfusionCardiovascular complicationsKidney injuryTreatment algorithmFever Prevention in Patients With Acute Vascular Brain Injury
Greer D, Helbok R, Badjatia N, Ko S, Guanci M, Sheth K, Diringer M, Mehta Y, Cava L, Hinduja A, Lele A, Sarwal A, Kulik T, Keller E, Smith G, Dennesen P, Dimitriadis K, Schonenberger S, Gunther A, Meisel A, Wolf S, Kollmar R, Barlinn K, Jeon S, Han M, Hong J, Lee R, Falcone G, Dashti S, Busl K, Ermak D, Berkeley J, Amory C, Swor R, DeGeorgia M, Green-LaRoche D, Thompson B, Hatton K, Sung G, Mehta C, Zurasky J, Da Silva I, James M, Aysenne A, Cervantes A, Devlin T, Chang I, Morris N, Venkatasubramanian C, Mushlschlegel S, Zachariah J, Chaudry F, Claassen J, Dangayach N, Choi H, Sadaka F, Miller C. Fever Prevention in Patients With Acute Vascular Brain Injury. JAMA 2024, 332: 1525-1534. PMID: 39320879, PMCID: PMC11425189, DOI: 10.1001/jama.2024.14745.Peer-Reviewed Original ResearchVascular brain injuryStandard care groupCare groupMajor adverse eventsPrimary outcomeStandard care patientsBlinded outcome assessmentIntensive care unit dischargeFunctional outcomesAdverse eventsBrain injuryFever preventionFever burdenPrincipal secondary end pointBetween-group differencesOpen-label randomized clinical trialPrevention groupFunctional recoveryPrincipal secondary outcomeCare patientsAssociated with worse outcomesMain OutcomesImpact functional outcomesSecondary end pointsTemperature management deviceThe Impact of Frailty on Patients With AF and HFrEF Undergoing Catheter Ablation A Nationwide Population Study
Mark J, Colombo R, Alfonso C, Llanos A, Collado E, Larned J, Giese G, Dyal M, Nanna M, Damluji A. The Impact of Frailty on Patients With AF and HFrEF Undergoing Catheter Ablation A Nationwide Population Study. JACC Advances 2024, 3: 101358. PMID: 39600986, PMCID: PMC11588852, DOI: 10.1016/j.jacadv.2024.101358.Peer-Reviewed Original ResearchAdverse cardiovascular eventsCatheter ablationAtrial fibrillationCardiovascular eventsHeart failureFrail patientsHospital lengthNonfrail patientsReducing major adverse cardiovascular eventsAssociated with worse outcomesMajor adverse cardiovascular eventsReduced ejection fractionHospital length of stayIn-hospital mortalityLonger hospital lengthAssociated with increased oddsDischarge dispositionInfluence of frailtyMultivariate regression analysisNationwide Inpatient SampleImpact of frailtyLength of stayPrevalence of frailtyEjection fractionJohns Hopkins Adjusted Clinical GroupsEffects of dapagliflozin in heart failure according to duration of type 2 diabetes: a patient-level meta-analysis of DAPA-HF and DELIVER
Butt J, De Boer R, Hernandez A, Inzucchi S, Kosiborod M, Koeber L, Lam C, Martinez F, Ponikowski P, Sabatine M, Shah S, Vaduganathan M, Jhund P, Solomon S, Mcmurray J. Effects of dapagliflozin in heart failure according to duration of type 2 diabetes: a patient-level meta-analysis of DAPA-HF and DELIVER. European Heart Journal 2024, 45: ehae666.1097. DOI: 10.1093/eurheartj/ehae666.1097.Peer-Reviewed Original ResearchEffects of dapagliflozinT2D durationHeart failureEjection fractionPrimary outcomeDAPA-HFCardiovascular deathNew York Heart Association functional classPro-B-type natriuretic peptide levelsN-terminal pro-B-type natriuretic peptide levelsComposite of worsening HFLeft ventricular ejection fractionPatient-level pooled analysisRisk of worsening HFAssociated with worse outcomesDuration of type 2 diabetesSafety of dapagliflozinPatient-level meta-analysisBenefits of dapagliflozinNatriuretic peptide levelsVentricular ejection fractionReduced ejection fractionHistory of T2DDuration of HFDuration of T2DClinical outcomes among patients with mitral valve regurgitation undergoing Impella-supported high-risk PCI
Abu-Much A, Grines C, Chen S, Batchelor W, Zhao D, Falah B, Maini A, Redfors B, Bellumkonda L, Bharadwaj A, Moses J, Truesdell A, Zhang Y, Zhou Z, Baron S, Lansky A, Basir M, O'Neill W, Cohen D. Clinical outcomes among patients with mitral valve regurgitation undergoing Impella-supported high-risk PCI. International Journal Of Cardiology 2024, 417: 132555. PMID: 39270940, DOI: 10.1016/j.ijcard.2024.132555.Peer-Reviewed Original ResearchLower left ventricular ejection fractionMitral valve regurgitationPercutaneous coronary interventionHigh-risk PCISevere MRHigh-risk percutaneous coronary interventionMR severityPCI-related complicationsValve regurgitationIII studiesHeart failureAssociated with worse outcomesPrevalence of heart failurePresence of severe MRLower body mass indexVentricular ejection fractionStatistical significanceHigh-risk PCI patientsBody mass indexTrace MREjection fractionModerate MRClinical outcomesMild MRWorse outcomesEffects of dapagliflozin according to QRS duration across the spectrum of left ventricular ejection fraction: An analysis of DAPA‐HF and DELIVER
Abdin A, Kondo T, Böhm M, Jhund P, Claggett B, Vaduganathan M, Hernandez A, Lam C, Inzucchi S, Martinez F, de Boer R, Desai A, Køber L, Sabatine M, Petersson M, Bachus E, Solomon S, McMurray J, Committees and Investigators O. Effects of dapagliflozin according to QRS duration across the spectrum of left ventricular ejection fraction: An analysis of DAPA‐HF and DELIVER. European Journal Of Heart Failure 2024, 26: 1952-1963. PMID: 39016033, DOI: 10.1002/ejhf.3350.Peer-Reviewed Original ResearchLeft ventricular ejection fractionSpectrum of left ventricular ejection fractionEffects of dapagliflozinProlongation of QRS durationVentricular ejection fractionQRS durationEjection fractionDAPA-HFHeart failurePrimary outcomeHF phenotypesPrimary composite outcome of cardiovascular deathMedian follow-up timeComposite outcome of cardiovascular deathOutcome of cardiovascular deathAssociated with worse outcomesReduced ejection fractionCardiac resynchronization therapyFollow-up timePrimary composite outcomeFavorable ventricular remodelingWorsening HFResynchronization therapyPharmacological therapyVentricular remodelingComparison of mortality and amputation after lower extremity bypass versus peripheral vascular intervention in patients with chronic limb-threatening ischemia and comorbid chronic kidney disease
Cleman J, Sierra J, Romain G, Capuano B, Scierka L, Callegari S, Jacque F, Peri-Okonny P, Nagpal S, Smolderen K, Mena-Hurtado C. Comparison of mortality and amputation after lower extremity bypass versus peripheral vascular intervention in patients with chronic limb-threatening ischemia and comorbid chronic kidney disease. Journal Of Vascular Surgery 2024, 80: 480-489.e5. PMID: 38608966, DOI: 10.1016/j.jvs.2024.04.016.Peer-Reviewed Original ResearchChronic limb-threatening ischemiaAll-cause mortalityLower extremity bypassPeripheral vascular interventionsComorbid chronic kidney diseaseLimb-threatening ischemiaComparison of mortalityPreference-sensitive treatment decisionsCox proportional hazards modelsRisk of deathInteraction termsProportional hazards modelLower-extremity bypassChronic kidney diseaseFine-Gray modelMortality riskVascular interventionsAmputationHazards modelOutcome dataFine-GrayAssociated with worse outcomesHigh riskKidney diseasePropensity scoreDeviation From Personalized Blood Pressure Targets Correlates With Worse Outcome After Successful Recanalization
Zhang Z, Pu Y, Yu L, Bai H, Duan W, Liu X, Nie X, Wen Z, Zheng L, Hu X, Leng X, Pan Y, Petersen N, Liu L. Deviation From Personalized Blood Pressure Targets Correlates With Worse Outcome After Successful Recanalization. Journal Of The American Heart Association 2024, 13: e033633. PMID: 38533955, PMCID: PMC11179781, DOI: 10.1161/jaha.123.033633.Peer-Reviewed Original ResearchConceptsBlood pressure targetsBlood pressureAutoregulatory limitsWorse outcomesAssociated with symptomatic intracranial hemorrhageAssociated with unfavorable clinical outcomesPressure targetsAssociated with worse outcomesAssociated with poor outcomesSignificant infarction growthSymptomatic intracranial hemorrhageUnfavorable clinical outcomeLarge vessel occlusion strokeAcute ischemic strokeMean velocity indexIntracranial hemorrhageBP management strategiesNeurological deteriorationClinical outcomesInfarct growthPoor outcomeEndovascular thrombectomyOcclusion strokeRecanalizationIschemic stroke
2023
Clinical impact of right ventricular pacing burden in patients with post-transcatheter aortic valve replacement permanent pacemaker implantation
Tsushima T, Al-Kindi S, Dallan L, Fares A, Yoon S, Wheat H, Attizzani G, Baeza C, Pelletier M, Arruda M, Mackall J, Thal S. Clinical impact of right ventricular pacing burden in patients with post-transcatheter aortic valve replacement permanent pacemaker implantation. EP Europace 2023, 25: 1441-1450. PMID: 36794441, PMCID: PMC10105841, DOI: 10.1093/europace/euad025.Peer-Reviewed Original ResearchConceptsRight ventricular pacing burdenTranscatheter aortic valve replacementVentricular pacing burdenPermanent pacemaker implantationPermanent pacemakerHeart failurePacing burdenPPM implantationRetrospective study of consecutive patientsLikelihood of heart failureStudy of consecutive patientsLeft ventricular ejection fractionAssociated with worse outcomesVentricular ejection fractionAortic valve replacementAtrial fibrillation burdenValve implantation depthConsecutive patientsEjection fractionValve replacementPost-TAVRClinical benefitPacemaker implantationRetrospective studySingle-centreThe role of local inflammation in complications associated with intubation in pediatric patients: A narrative review
Amaya S, Murillo M, Pérez M, Cervera H, Andrade M, Zuñiga M, Barreto N, Daza M, Carvajal L, Alarcón C, Aponte L, Olbrecht V. The role of local inflammation in complications associated with intubation in pediatric patients: A narrative review. Pediatric Anesthesia 2023, 33: 427-434. PMID: 36719267, DOI: 10.1111/pan.14643.Peer-Reviewed Original ResearchConceptsPediatric patientsOrotracheal intubationAssociated with worse outcomesComplications associated with intubationOral bacterial floraAdvanced airway managementIntubated pediatric patientsNarrative reviewProlonged intubationTreatment optionsWorse outcomesLocal inflammationAirway managementPatient populationExperience complicationsInflammatory mediatorsReduce inflammationInflammatory responseIntubationPatientsComplicationsPresence of traumaInflammationExcessive manipulationBacterial flora
2022
Clinical Characteristics and Prognosis of MINOCA Caused by Atherosclerotic and Nonatherosclerotic Mechanisms Assessed by OCT
Zeng M, Zhao C, Bao X, Liu M, He L, Xu Y, Meng W, Qin Y, Weng Z, Yi B, Zhang D, Wang S, Luo X, Lv Y, Chen X, Sun Q, Feng X, Gao Z, Sun Y, Demuyakor A, Li J, Hu S, Guagliumi G, Mintz G, Jia H, Yu B. Clinical Characteristics and Prognosis of MINOCA Caused by Atherosclerotic and Nonatherosclerotic Mechanisms Assessed by OCT. JACC Cardiovascular Imaging 2022, 16: 521-532. PMID: 36648054, DOI: 10.1016/j.jcmg.2022.10.023.Peer-Reviewed Original ResearchConceptsMajor adverse cardiac eventsOptical coherence tomographyTarget lesion revascularizationCardiac deathLesion revascularizationPredictors of Major Adverse Cardiac EventsAssociated with worse outcomesSpontaneous coronary artery dissectionClinical diagnosis of MIPrognosis of MINOCAMechanisms of MINOCAAdverse cardiac eventsNonobstructive coronary arteriesPrognosis of patientsCoronary artery dissectionDiagnosis of MIOCT findingsAtherosclerotic causeCardiac eventsClinical characteristicsClinical outcomesArtery dissectionComposite endpointMINOCACoronary spasmClinical factors associated with outcome in solid tumor patients treated with immune-checkpoint inhibitors: a single institution retrospective analysis
Qin Q, Jun T, Wang B, Patel V, Mellgard G, Zhong X, Gogerly-Moragoda M, Parikh A, Leiter A, Gallagher E, Alerasool P, Garcia P, Joshi H, MBBS, Galsky M, Oh W, Tsao C. Clinical factors associated with outcome in solid tumor patients treated with immune-checkpoint inhibitors: a single institution retrospective analysis. Discover Oncology 2022, 13: 73. PMID: 35960456, PMCID: PMC9374856, DOI: 10.1007/s12672-022-00538-6.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsFamily history of cancerDisease control rateProgression free survivalOverall response rateHistory of cancerICI responseOverall survivalCell carcinomaSolid tumor patients treated with immune checkpoint inhibitorsPatients treated with immune checkpoint inhibitorsPatients treated with immune-checkpoint inhibitorsRetrospective analysisClinical factors associated with outcomesType of immune checkpoint inhibitorFamily historyHead and neck squamous cell carcinomaImmune checkpoint inhibitor therapyDiagnosis of non-small cell lung cancerPredictive biomarkers of responseNon-small cell lung cancerClinical predictors of responseNeck squamous cell carcinomaMultivariate Cox proportional hazards modelAssociated with worse outcomesOP0252 FACTORS ASSOCIATED WITH SEVERE COVID-19 OUTCOMES IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHY: RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE PHYSICIAN-REPORTED REGISTRY
Yeoh S, Gianfrancesco M, Lawson-Tovey S, Hyrich K, Strangfeld A, Gossec L, Carmona L, Mateus E, Schaefer M, Richez C, Hachulla E, Holmqvist M, Scirè C, Hasseli R, Jayatilleke A, Hsu T, D'Silva K, Pimentel-Quiroz V, del Mercado M, Shinjo S, Neto E, Rocha L, Montandon A, Jordan P, Sirotich E, Hausmann J, Liew J, Jacobsohn L, Gore-Massy M, Sufka P, Grainger R, Bhana S, Wallace Z, Robinson P, Yazdany J, Machado P, Alliance C. OP0252 FACTORS ASSOCIATED WITH SEVERE COVID-19 OUTCOMES IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHY: RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE PHYSICIAN-REPORTED REGISTRY. Annals Of The Rheumatic Diseases 2022, 81: 165-166. DOI: 10.1136/annrheumdis-2022-eular.3235.Peer-Reviewed Original ResearchIdiopathic inflammatory myopathiesIdiopathic inflammatory myopathy patientsHigh disease activityDisease activityOdds ratioGrant/research supportAstra ZenecaInflammatory myopathiesSynthetic DMARDsCOVID-19 severity scaleCOVID-19 outcomesBristol-Myers SquibbMultivariate logistic regression analysis of factorsBoehringer IngelheimDisease-modifying anti-rheumatic drugsIIM casesSanofi GenzymeAssociated with worse outcomesFactors associated with severe COVID-19 outcomesMultivariate logistic regression analysisExposure to rituximabOutcomes of patientsConventional synthetic DMARDsAnti-rheumatic drugsLogistic regression analysis of factors
2021
Racial differences in cardiopulmonary outcomes of hospitalized COVID-19 patients with acute kidney injury
Egbuche O, Abe T, Nwokike S, Jegede O, Mezue K, Olanipekun T, Onuorah I, Echols M. Racial differences in cardiopulmonary outcomes of hospitalized COVID-19 patients with acute kidney injury. Reviews In Cardiovascular Medicine 2021, 22: 1667-1675. PMID: 34957809, PMCID: PMC9054458, DOI: 10.31083/j.rcm2204174.Peer-Reviewed Original ResearchConceptsIn-hospital cardiac eventsCOVID-19 patientsIn-hospital mortalityCardiac eventsGrady Health SystemNon-blacksAssociated with increased disease burdenCardiopulmonary outcomesPolymerase-chain-reaction assayAssociated with higher riskMortality of hospitalized COVID-19 patientsAcute respiratory distress syndromeAssociated with worse outcomesIn-hospital acute kidney injuryMechanism of injuryOutcomes of hospitalized COVID-19 patientsPresence of AKIHospitalized COVID-19 patientsRespiratory distress syndromeProportion of patientsAcute kidney injuryPrimary composite outcomeRetrospective cohort studyImpact of AKIHealth systemPre-existing cardiovascular disease, acute kidney injury, and cardiovascular outcomes in hospitalized blacks with COVID-19 infection.
Egbuche O, Jegede O, Abe T, Wagle B, Huynh K, Hayes D, Campbell M, Mezue K, Ram P, Nwokike S, Desai R, Effoe V, Kpodonu J, Morgan J, Ofili E, Onwuanyi A, Echols M. Pre-existing cardiovascular disease, acute kidney injury, and cardiovascular outcomes in hospitalized blacks with COVID-19 infection. Am J Cardiovasc Dis 2021, 11: 212-221. PMID: 34084656, PMCID: PMC8166582.Peer-Reviewed Original ResearchIn-hospital cardiac eventsPre-existing cardiovascular diseaseAcute kidney injuryIn-hospital mortalityAcute respiratory distress syndromeAssociated with increased oddsCardiac eventsCOVID-19 patientsKidney injuryPresence of acute kidney injuryAssociated with increased odds of in-hospital mortalityPolymerase-chain-reaction assayHigher risk of in-hospital mortalityIn-hospital acute kidney injuryAssociated with worse outcomesRisk of in-hospital mortalityCardiovascular diseaseHospitalized COVID-19 patientsRespiratory distress syndromeOdds of in-hospital mortalityAssociated with higher riskRetrospective cohort studyMortality of COVID-19 patientsIn-hospital mortality of COVID-19 patientsDistress syndrome
2020
Assessment of right ventricular function following left ventricular assist device (LVAD) implantation—The role of speckle‐tracking echocardiography: A meta‐analysis
Barssoum K, Altibi A, Rai D, Kharsa A, Kumar A, Chowdhury M, Elkaryoni A, Abuzaid A, Baibhav B, Parikh V, Masri A, Amsallem M, Nanda N. Assessment of right ventricular function following left ventricular assist device (LVAD) implantation—The role of speckle‐tracking echocardiography: A meta‐analysis. Echocardiography 2020, 37: 2048-2060. PMID: 33084128, DOI: 10.1111/echo.14884.Peer-Reviewed Original ResearchConceptsRight ventricle free wall strainRight ventricle global longitudinal strainRight ventricular failureSpeckle-tracking echocardiographyRight ventricular failure patientsLeft ventricular assist deviceStandardized mean differenceTransthoracic echocardiographyPrediction of right ventricular failureSubgroup analysisAssessment of right ventricular functionVentricular assist deviceOdds ratioAssociated with worse outcomesFree wall strainGlobal longitudinal strainRight ventricular functionLeft ventricular assist device recipientsMeta-analysisMeta-analysis of published literaturePooled odds ratioRandom-effects modelNo significant differenceVentricular failureVentricular function
2019
Patients with an extremely high prostate-specific antigen at prostate cancer diagnosis: A single institution analysis.
Qin Q, Bikkasani K, Oh W, Liaw B, Galsky M, Tsao C. Patients with an extremely high prostate-specific antigen at prostate cancer diagnosis: A single institution analysis. Journal Of Clinical Oncology 2019, 37: 309-309. DOI: 10.1200/jco.2019.37.7_suppl.309.Peer-Reviewed Original ResearchProstate specific antigenCastration-resistant prostate cancerProstate cancer diagnosisAndrogen deprivationLymph nodesTreatment selectionProstate cancerResponse to first line therapyHigher prostate specific antigenAssociated with worse outcomesMedian PSA nadirFirst line therapySite of metastasisCancer diagnosisIRB-approved databaseProstate-specific antigenResponse 6 monthsResponse to treatmentPSA nadirLine therapyMetastatic diseaseCancer ptsMedian ageClinical presentationClinical characteristicsEffects of high dose atorvastatin before elective percutaneous coronary intervention on highly sensitive troponin T and one year major cardiovascular events; a randomized clinical trial
Pourhosseini H, Lashkari R, Aminorroaya A, Soltani D, Jalali A, Tajdini M. Effects of high dose atorvastatin before elective percutaneous coronary intervention on highly sensitive troponin T and one year major cardiovascular events; a randomized clinical trial. IJC Heart & Vasculature 2019, 22: 96-101. PMID: 30671535, PMCID: PMC6328087, DOI: 10.1016/j.ijcha.2018.12.003.Peer-Reviewed Original ResearchGroup AGroup BElective PCIPatients of group ACompared to group BAssociated with worse outcomesElective percutaneous coronary interventionHigh dose atorvastatinMedian follow-upElevated cardiac enzymesSensitivity troponin THigh-dose treatmentOccurrence of MACEPretreatment of patientsProportional hazards regression modelsMajor cardiovascular eventsHazards regression modelsPercutaneous coronary interventionDose atorvastatinCardiac enzymesDaily dosageStable anginaWorse outcomesCardiovascular eventsFollow-up
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply